arrow
O

Oriol Mirallas

Department of Investigational Cancer Therapeutics
H指数:16
被引数:1,053

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical determinants of survival outcomes and acute toxicity after adoptive cellular therapy for solid tumors
2026-07-300
OA
Targeting claudins in gastric cancer: A novel GLOWing strategy in the SPOTLIGHT

靶向胃癌细胞紧密连接蛋白claudins:一种新颖的GLOWing策略在SPOTLIGHT

2026-04-230
PRE
Evolving landscape of targeted therapies in early phase clinical trials

靶向疗法在早期临床试验中的演变格局

2026-04-120
PRE
Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study

真实世界下一代测序揭示的神经胶质瘤的临床可操作性: 一项多中心研究

2026-01-060
OAAI
DUAL INHIBITION OF POST-RADIOGENIC REVASCULARIZATION IN NEWLY-DIAGNOSED GLIOBLASTOMA: FINAL RESULTS OF THE MULTICENTRIC PHASE 1/2 GLORIA TRIAL

放射后新生血管生成的双重抑制在新诊断胶质母细胞瘤中的应用:多中心GLORIA试验1/2期最终结果

2025-11-010
OAAI
Prediction of 90-day mortality among cancer patients with unplanned hospitalisation: a retrospective validation study of three prognostic scores

癌症患者非计划住院90天死亡率的预测:三种预后评分的回顾性验证研究

2025-07-010
OA
Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study

预测住院癌症患者90天死亡率的预后模型的开发 (PROMISE工具): 一项前瞻性观察研究

2024-11-010
OA
Tumor whole genome sequencing-based ultrasensitive ctDNA analysis as an early biomarker for clinical outcome in immune checkpoint inhibitor (ICI) phase I clinical trials (Ph1) and a tool for beyond progressive disease by iRECIST

基于肿瘤全基因组测序的极灵敏循环肿瘤DNA分析,作为免疫检查点抑制剂(ICI)I期临床试验(Ph1)中预测临床结局的早期生物标志物,以及通过iRECIST实现疾病进展后评估的工具。

2024-09-010
PRE
Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
2024-04-303
PRE
Predictive factors for drug-induced liver injury in patients with ER-positive HER2-negative metastatic breast cancer treated with first-line cyclin-dependent kinase 4/6 inhibitors
2023-10-010
PRE
The PRognostic Oncologic Plantology (PROP) website tool predicts 30-day mortality in hospitalized cancer patients on treatment

预后肿瘤学 (PROP) 网站工具预测住院癌症患者接受治疗的30天死亡率

2023-10-010
OA
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials
MED
IF11.8
2023-10-015
OA